News Archives | Page 2 of 9 | American Parkinson Disease Association

New drug approved for OFF episodes

Posted on April 27, 2020 by Phil Franchina

Today, Neurocrine Biosciences announced that the Food and Drug Administration (FDA) approved ONGENTYS ® (opicapone), a new medication for...see more treatment of Parkinson’s disease (PD). Opicapone is a catechol-O-methyltransferase (COMT) inhibitor to be used once-daily as an add-on treatment to levodopa for patients who are experiencing OFF time with their current medication regimen. Opicapone is in […]

CORONAVIRUS DISEASE 2019 AND THE PD COMMUNITY

Posted on March 20, 2020May 20, 2022 by Phil Franchina

APDA COVID-19 INFORMATION & RESOURCES: The American Parkinson Disease Association (APDA) continues to monitor the COVID-19 situation, particularly as...see more it relates to our Parkinson’s disease (PD) community. This page is updated regularly as new information becomes available. Vaccines: Three COVID-19 vaccines have been approved for use in the United States — one manufactured by Pfizer/BioNTech, […]

The 26th Annual Parkinson’s Unity Walk

Posted on January 13, 2020January 13, 2020 by Phil Franchina

The American Parkinson Disease Association (APDA) is a proud partner of the 26th Annual Parkinson’s Unity Walk taking place on...see more Saturday, April 25, 2020 in Central Park, New York City. 100% of donations raised by the event will go to research funded by the leading PD foundations, including APDA. In addition to raising awareness and funds […]

The FDA approves F-Dopa PET imaging to aid in early diagnosis of Parkinson’s disease

Posted on January 8, 2020January 8, 2020 by Dr. Rebecca Gilbert

The FDA recently approved Flourodopa...see more F18 (F-Dopa), a radioactive tracer for positron emission tomography (PET) that can help visualize the nerve endings of dopaminergic neurons. It can be used to help in the diagnosis of Parkinson’s disease (PD) and other parkinsonian […]

Deep brain stimulation and swimming

Posted on December 4, 2019December 4, 2019 by Phil Franchina

Deep brain stimulation (DBS) is a surgical treatment for Parkinson’s disease (PD) symptoms in...see more which small wires are inserted deep into the brain to deliver electrical current that allows for maintenance of more normal movement. DBS is particularly helpful for those with medication-resistant tremors as well as for those who […]

Promising results from the University of Pittsburgh APDA Center for Advanced Research

Posted on October 24, 2019December 12, 2019 by Phil Franchina

Building off of pivotal APDA-funded work highlighted...see more here, Dr. J. Timothy Greenamyre and his team, published a new study investigating the role of Leucine-rich Repeat Kinase (LRRK2) in the development of Parkinson’s disease (PD). LRRK2 is known to be mutated in a small […]

Taking Parkinson’s education to the farmers market: educating under-served communities

Posted on September 16, 2019September 16, 2019 by Phil Franchina

Dr. Lynda Nwabuobi, Movement Disorder Fellow at Columbia Presbyterian...see more Medical Center in New York City, attended APDA’s Diversity in Parkinson’s Disease (PD) Research Conference in May and was inspired. Dr. Nwabuobi had just spent the day learning about health care disparities in PD care, low […]

New medication, Istradefylline, gets approved for Parkinson’s disease

Posted on September 4, 2019 by Phil Franchina

On August 27, 2019, pharmaceutical company Kyowa Kirin received FDA approval...see more for Istradefylline, a new medication for Parkinson’s disease (PD) to be used as an add-on treatment to carbidopa/levodopa for those experiencing OFF episodes. (For more information on OFF periods in PD, please see this recent APDA […]

APDA Seed Funding Leads to Prestigious NIH Research Grant

Posted on August 16, 2019August 16, 2019 by Phil Franchina

APDA is exceptionally proud to congratulate Dr. Beom-Chan Lee, APDA Research...see more Grant awardee on receiving a recently-awarded National Institutes of Health (NIH) R21 grant.

APDA-funded research finds new role for alpha-synuclein

Posted on July 30, 2019July 31, 2019 by Phil Franchina

This new understanding of alpha-synuclein’s function could open up new ways of thinking...see more about treatments for Parkinson's disease.

What is Parkinson’s Disease?

Parkinson’s Resource Library

Research

Get Involved

Important News & Updates from APDA

New drug approved for OFF episodes

CORONAVIRUS DISEASE 2019 AND THE PD COMMUNITY

The 26th Annual Parkinson’s Unity Walk

The FDA approves F-Dopa PET imaging to aid in early diagnosis of Parkinson’s disease

Deep brain stimulation and swimming

Promising results from the University of Pittsburgh APDA Center for Advanced Research

Taking Parkinson’s education to the farmers market: educating under-served communities

New medication, Istradefylline, gets approved for Parkinson’s disease

APDA Seed Funding Leads to Prestigious NIH Research Grant

APDA-funded research finds new role for alpha-synuclein

Can You Be Too Young to Get Parkinson’s Disease?

Parkinson's disease: Move regularly with intensity to delay symptoms

Update on Parkinson’s Disease Therapy

Dr. Rebecca Gilbert MD, PHD of the APDA discusses Focused Ultrasound, DBS + more

AMERICAN PARKINSON DISEASE ASSOCIATION KICKS-OFF PARKINSON’S DISEASE AWARENESS MONTH & CELEBRATES THE UNSHAKEABLE SPIRIT OF PEOPLE LIVING WITH PD

Pushing for Progress: American Parkinson Disease Association Funding To Accelerate Scientists’ Pursuit for Answers

THE AMERICAN PARKINSON DISEASE ASSOCIATION (APDA) ANNOUNCES NEW LEADERSHIP FOR BOARD OF DIRECTORS

American Parkinson Disease Association Releases Symptom Tracker Mobile App With Expanded Features

Dhivy^TM, a carbidopa/levodopa fractionated tablet, is now available

New Treatment for Slowness & Stiffness in Parkinson’s Disease

APDA funding is critical to new research in understanding Levodopa-induced dyskinesias

EXCITING GENETIC DISCOVERIES FUNDED BY APDA

Support Our Mission

Support Our Mission

Subscribe to get updates from APDA and helpful Parkinson’s info!